XML 26 R12.htm IDEA: XBRL DOCUMENT v3.24.2
Revenue from Contracts with Customers
 12 Months Ended
Apr. 30, 2024
Revenue from Contract with Customer [Abstract]  
Revenue from Contracts with Customers Revenue from Contracts with Customers
Oncology Services Revenue

The following table represents disaggregated revenue for the twelve months ended April 30, 2024 and 2023:
Year Ended April 30,
 20242023
Pharmacology services$47,035 $50,708 
Other TOS revenue3,102 3,046 
Personalized oncology services18 116 
Total oncology services revenue$50,155 $53,870 
Other TOS revenue represents additional services provided to the Company's pharmaceutical and biotechnology customers, specifically flow cytometry services and SaaS provided via our Lumin Bioinformatics software.
Contract Balances
Contract assets include unbilled amounts typically resulting from revenue recognized in excess of the amounts billed to the customer for which the right to payment is subject to factors other than the passage of time. These amounts may not exceed their net realizable value. Contract assets are classified as current. Contract liabilities consist of customer payments received in advance of performance and billings in excess of revenue recognized, net of revenue recognized from the balance at the beginning of the period. Contract assets and liabilities are presented on the balance sheet on a net contract-by-contract basis at the end of each reporting period. Refer to Note 3 for related balances.